Results 171 to 180 of about 20,950 (257)

Psoriasis treatment with biologics: beyond tumor necrosis factor α inihibitors – The present and the future [PDF]

, 2012
A psoríase é uma doença inflamatória crónica multissistémica, mediada por células T, com elevado grau de morbilidade. A investigação na área da psoríase tem sido intensa, resultando num conhecimento mais porme- norizado da sua patogenia, e consequente ...
Carvalho, S., Selores, M., Torres, T.
core  

S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditäten

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 270-284, February 2026.
Zusammenfassung Der vorliegende Teil 2 der aktualisierten S3‐Leitlinie zur Therapie der Psoriasis vulgaris bietet Empfehlungen zur Therapieauswahl in besonderen klinischen Situationen sowie bei Vorliegen von Komorbidität. Ein Schwerpunkt des Updates liegt im Kapitel Screening auf Tuberkulose sowie in der Therapieauswahl und im Management bei latenter ...
Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen   +25 more
wiley   +1 more source

Results from the 32‐week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 274-284, February 2026.
During the extension phase of the 32‐week DISCREET trial, apremilast treatment in patients with moderate to severe genital psoriasis led to clinically meaningful improvements in disease severity (modified genital PGA, overall sPGA, BSA), symptoms (genital itch, GPSS), and quality of life (DLQI, DLQI‐Q9), with safety outcomes consistent with prior ...
Joseph F. Merola, Lyn Guenther, Charles Lynde, Kim A. Papp, Lawrence Charles Parish, Paul Yamauchi, Sue Cheng, Hamid Amouzadeh, Cynthia Deignan, Shauna Jardon, Mindy Chen, Andreas Pinter   +11 more
wiley   +1 more source

Psoriasis Skin Clearance, Body Mass Index, and Lifestyle Behaviors

International Journal of Dermatology, Volume 65, Issue 3, Page 596-599, March 2026.
Annika Smith, Melvin Li, Kelvin Truong, Clara Chow, Sarah Zaman   +4 more
wiley   +1 more source

Clinical Characteristics and a New Classification System of Mono‐Segmental Thoracic and Lumbar Nonfusion in Patients With Ankylosing Spondylitis

Orthopaedic Surgery, Volume 18, Issue 2, Page 270-278, February 2026.
In regard to the mono‐segmental thoracic and lumbar nonfusion in patients with ankylosing spondylitis, we built a new classification system based on CT and MRI data and describe its clinical distribution characteristics and occurrence risk factors for the first time. ABSTRACT Study Design Retrospective cohort study.
Bingchuan Liu, Zhengguang Wang, Fang Zhou, Yun Tian, Zhishan Zhang   +4 more
wiley   +1 more source

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

ClinicoEconomics and Outcomes Research, 2018
Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l.
Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM   +6 more
doaj  

Low satisfaction with medical care among patients with hidradenitis suppurativa: A multicenter study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page e95-e99, February 2026.
Kerstin Wolk, Giorgia Cugno, Georgios Kokolakis, Sylke Schneider‐Burrus, Dagmar Wilsmann‐Theis, Katharina Assaf, Rotraut Moessner, Christian Kromer, Falk G. Bechara, Nessr Abu Rached, Wiebke K. Peitsch, Lisa C. Schneider, Andreas Happ, Valentina Siddi, Diana Kubitzki, Durdana Groß, Markus Friedrich, Staffan Vandersee, Khusru Asadullah, Robert Sabat   +19 more
wiley   +1 more source

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab

Clinical, Cosmetic and Investigational Dermatology, 2016
Mona Malakouti, Sharon E Jacob, Nancy J Anderson Department of Dermatology, Loma Linda University, Loma Linda, CA, USA Abstract: Psoriasis is a chronic inflammatory skin disease that has a negative impact on psychosocial well-being and ...
Malakouti M, Jacob SE, Anderson NJ
doaj  

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years. [PDF]

Rheumatology (Oxford)
Mease PJ, Coates LC, Gaillez C, Shew A, Bao W, Ritchlin CT.   +5 more
europepmc   +1 more source

Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report. [PDF]

SAGE Open Med Case Rep
Te B, Roesler J, Kunimoto B.
europepmc   +1 more source